It has been unraveled that the tumor microenvironment (TME) contains macrophages skewed toward the tumor-promoting type (TAM) and T-cells, with the latter being potential targets for, e.g., Nivolumab and Ipilimumab antibody therapy targeting the T-cell immune checkpoints PD-1 and CTLA4. This evidence concerns the gene CTLA4 and neoplasm.